ERBB2 and breast cancer: The higher expression level of BTN3A2 is related to the good prognosis of HR negative, HER2 positive (HR-/HER2+) breast cancer patients, and also to the distant metastasis-free survival (DMFS) rate of breast cancer patients 61.